1 Copenhagen Muscle Research Centre, Department of Medical Physiology, Panum Institute, DK-2200, Copenhagen, and 2 Department of Human Physiology, August Krogh Institute, University of Copenhagen, DK-2100 Copenhagen, Denmark; 3 Institute of Sports Medicine, Third Hospital, Beijing University, 100083 Beijing, China; and 4 Division of Molecular Physiology, School of Life Sciences, Wellcome Trust Biocentre, Dundee University, Dundee DD1 5EH, Scotland, United Kingdom
![]() |
ABSTRACT |
---|
![]() ![]() ![]() ![]() ![]() ![]() ![]() |
---|
AMP-activated protein kinase (AMPK)
may mediate the stimulatory effect of contraction and
5-aminoimidazole-4-carboxamide ribonucleoside (AICAR) on glucose
transport in skeletal muscle. In muscles with different fiber type
composition from fasted rats, AICAR increased 2-deoxyglucose transport
and total AMPK activity approximately twofold in epitrochlearis (EPI),
less in flexor digitorum brevis, and not at all in soleus muscles.
Contraction increased both transport and AMPK activity more than AICAR
did. In EPI muscles, the effects of AICAR and contractions on glucose
transport were partially additive despite a lower AMPK activity with
AICAR compared with contraction alone. In EPI from fed rats, glucose
transport responses were smaller than what was seen in fasted rats, and
AICAR did not increase transport despite an increase in AMPK activity.
AICAR and contraction activated both 1- and
2-isoforms of AMPK. Expression of both isoforms varied
with fiber types, and
2 was highly expressed in nuclei.
In conclusion, AICAR-stimulated glucose transport varies with muscle
fiber type and nutritional state. AMPK is unlikely to be the sole
mediator of contraction-stimulated glucose transport.
glycogen; diet; metabolism; signaling; GLUT4
![]() |
INTRODUCTION |
---|
![]() ![]() ![]() ![]() ![]() ![]() ![]() |
---|
IN SKELETAL MUSCLE, glucose transport is increased by insulin and muscle contraction via translocation of the intracellular glucose transporter GLUT4 to the plasma membrane and T-tubules (for review see Refs. 24, 44). These two stimuli have additive effects on glucose transport, suggesting that they act via at least partially independent pathways (40, 42). This view is further supported by the finding that each of the two stimuli recruits distinct pools of intracellular GLUT4 vesicles to the surface membrane of the muscle fibers (8, 15, 43). The insulin-sensitive pool appears to constitute a specialized population of vesicles that is distinct from the endosomal system (1, 43, 48). In contrast, contraction recruits GLUT4 vesicles from recycling endosomes defined by the presence of transferrin receptors (36, 43). Not surprisingly, then, the signal transduction pathways turn out to be distinct. Studies have shown that wortmannin, a phosphatidylinositol 3-kinase inhibitor, selectively impairs insulin- but not contraction-stimulated glucose transport (35, 37, 55). Until recently, the signaling mechanism by which contraction recruits GLUT4 transporters has remained obscure. A rise in the cytoplasmic Ca2+ concentration, as takes place during excitation-contraction coupling, has for a number of years been thought to be involved in contraction-induced glucose transport (for review see Ref. 27). The identification of a specific Ca2+ sensor has been elusive, but recently the protein kinase C inhibitor calphostin C has been shown to selectively impair contraction- but not insulin-stimulated glucose transport (29).
The possibility that another pathway may also be involved in
contraction-induced activation of glucose transport was suggested by
the recent observation that perfusion of rat hindquarters with the
pharmacological agent 5-aminoimidazole-4-carboxamide ribonucleoside (AICAR) resulted in increased glucose uptake (38). AICAR
is known to be taken up into cells and converted to the
monophosphorylated form ZMP, which mimics effects of AMP on
AMP-activated protein kinase (AMPK), including both direct allosteric
activation and promotion of phosphorylation by an upstream kinase
(9, 25, 26, 49). AMPK is a heterotrimeric enzyme,
consisting of a catalytic subunit () and two regulatory subunits
(
and
). Several isoforms of all three subunits have been
identified (7, 21, 33). AMPK has been suggested to act as
a "low-fuel warning system," being switched on by depletion of ATP
and then subsequently initiating energy-saving measures and
ATP-generating processes (20). Because AMPK is known
to be activated in muscle by contraction (28, 51,
52), it was then speculated that the mechanism by which AICAR is
able to increase muscle glucose uptake is similar to the mechanism by
which contraction and hypoxia (both of which increase AMP in muscle)
stimulate glucose transport (38). In favor of this view,
it has been found that acute exposure to AICAR increases 2-deoxyglucose
(2-DG) transport in skeletal muscle in a wortmannin-insensitive manner
(3, 23) and induces GLUT4 translocation to the muscle
fiber surface membrane (34). Furthermore, the effect of
AICAR on glucose transport was additive to the effect of insulin but
not additive to the effect of contractions (3, 23). Most
of the cited studies have been performed on muscles from fasted or
starved rats and on muscles containing a high proportion of fast-twitch
type IIb fibers. However, in a recent study, high glycogen levels
inhibited contraction-induced AMPK activation in slow-twitch, but not
in fast-twitch, muscles (12). This suggests that
mechanisms involved in contraction-stimulated glucose
transport may be fiber type dependent and/or influenced by the
nutritional state. A fiber type-related plasticity of AMPK regulation
is also suggested by the in vivo effect of AICAR on muscle glucose
transport (3) and GLUT4 expression (5).
In the present work, we have studied the acute effects of AICAR and
contraction on glucose transport and AMPK activity in three different
muscles with distinct fiber type composition from both fed and fasted
rats. Furthermore, we have looked for fiber type-dependent expression
and subcellular localization of the two isoforms of the catalytic
subunit of AMPK, since it has been reported that it is primarily the
2-, and not the
1-isoform, that is
activated by muscle contractions (51, 53).
![]() |
MATERIALS AND METHODS |
---|
![]() ![]() ![]() ![]() ![]() ![]() ![]() |
---|
Materials. 2-DG, glucose, bovine serum albumin fraction V (BSA), pyruvic acid, AICAR, ATP, ADP, AMP, IMP, and ZMP were from Sigma. 2-Deoxy-D-[3H]glucose and [14C]sucrose were from Du Pont-NEN. Polyvinylidene difluoride (PVDF) membranes (Sequi-Blot) were from Bio-Rad and the enhanced chemiluminescence kit from Amersham Pharmacia. Hexokinase, glucose-6-phosphate dehydrogenase, NADP, and NAD+ were from Boehringer, and other reagents were of analytical grade.
Muscle incubation and stimulation.
The experiments were approved by the Animal Experiments Inspectorate of
the Danish Ministry of Justice. Fed or overnight-fasted male Wistar
rats (60-70 g body wt), obtained from Charles River Laboratories
(Sulzfeld, Germany), were anesthetized with an intraperitoneal injection of pentobarbital sodium (5 mg/100 g body wt). The rats were
perfused through the left ventricle for 1 min (flow 20 ml/min) with
Krebs-Henseleit bicarbonate-buffered medium containing 8 mM glucose, 1 mM pyruvic acid, and 0.2% BSA. The epitrochlearis (EPI), flexor
digitorum brevis (FDB), and soleus muscles, each enriched with a
distinct fiber type (Table 1), were
gently dissected free with intact tendons at both ends and incubated
for 30 min in perfusion medium in test tubes at 29°C. The medium was
continuously gassed with 95% O2-5% CO2. After
the 30-min equilibration period, muscles were placed at 37°C in
glucose-free Krebs-Henseleit buffer containing 2 mM pyruvic acid and
0.2% BSA for 60 min with or without various concentrations of AICAR
(see legends to figures). When the effect of contractions was studied,
muscles were directly electrically stimulated to contract during the
last 11 min of incubation at 37°C. A small clip was attached to each
of the two tendons, and the muscle was vertically suspended in
incubation medium, with or without AICAR, with the upper end attached
to a force transducer connected to a computer for measurement of total
force output (31). Electrodes were placed at both ends of
the muscle, and 2 × 5 min of repeated tetanic contractions, separated by a 1-min break, were produced by stimulation with 25 V in
200-ms trains of 100 Hz, each impluse being 0.2 ms, and with a train
frequency of 1/s (42). During the initial contractions, the length of the muscle was adjusted to yield maximum force; i.e., the
muscle was suspended at its resting length.
|
Measurement of 2-DG transport.
2-DG transport was measured as described (29). Briefly,
immediately after incubation with or without contractions, muscles were
placed in test tubes at 29°C for measurement of glucose transport. Transport was measured as
2-deoxy-D-[3H]glucose
([3H]2-DG) uptake, with [14C]sucrose as
extracellular marker. Isotopes and unlabeled sugars were added to the
incubation medium (Krebs-Henseleit buffer containing 2 mM pyruvic acid
and 0.2% BSA with or without AICAR) to yield final concentrations of
0.43 µCi [3H]2-DG and 0.32 µCi
[14C]sucrose/ml and 1 mM of both unlabeled 2-DG and
sucrose. After 10-min exposure to isotopes, muscles were briefly
blotted on filter paper and immediately frozen in liquid nitrogen.
Muscles were stored at 80°C until analyzed.
Measurement of metabolites and total and isoform-specific AMPK
activity and expression by Western blot.
Muscles were quickly removed from the incubation medium and
freeze-clamped with tongs cooled in liquid nitrogen and stored at
80°C until analyzed. For studies of contractions, muscles were
freeze clamped while still connected to the electrodes and still
contracting. Glycogen was determined by a hexokinase method after
hydrolysis with HCl (32). Nucleotide concentrations were determined in neutralized perchloric acid extracts by reverse-phase HPLC (50). Separation was achieved by a 30-min gradient
elution using a Hibar Lichrosphere 100 CH-18/2 (Merck) column (250 × 4 mm). The linear gradient program for the mobile phase was as
follows: 0 min, 100% A; 0.1-4 min, 75% A; 4-17 min, 0% A;
17-22 min, 0-100% A. The composition of buffer A
was 150 mM ammonium phosphate (pH 5.80). Buffer B also
contained 150 mM ammonium phosphate with 20% methanol and 2%
acetonitrile added as organic modifiers (pH 5.45). Separation was
achieved at room temperature with a flow of 0.8 ml/min. Detection was
at 254 nm, and peaks were identified by comparison of retention times
with commercially obtained compounds.
Determination of muscle fiber type composition and
immunohistochemical localization of AMPK -subunits.
Pieces of muscles were mounted in Tissue-Tek (Miles, Elkhart, IN) and
frozen in isopentane, cooled to its freezing point in liquid nitrogen.
Serial transverse sections (20 µm) of the embedded muscle pieces were
cut with a microtome at
20°C, mounted on glass slides, and stained
for myofibrillar ATPase to identify fiber types (4). For
localization of AMPK
1- and
2-subunits,
transverse sections were fixed for 10 min in 2% depolymerized
paraformaldehyde in 0.1 M phosphate buffer and blocked for 30 min with
50 mM glycine, 0.25% BSA, 0.04% saponin, and 0.05% sodium azide in
PBS. Sections were then incubated for 1.5 h with primary
antibodies diluted in blocking buffer. As primary antibodies, the
previously described isoform-specific sheep anti-
1-and
anti-
2-AMPK antibodies were used at a concentration of
0.2 µg/ml IgG together with a mouse monoclonal antibody against the
slow myosin heavy-chain isoform (Sigma) for fiber type identification.
After three washes of 10 min each in blocking buffer, sections were
incubated for 45 min with secondary antibody conjugates (Alexa Fluor
488-labeled anti-sheep IgG and Alexa Fluor 594-labeled anti-mouse IgG
from Molecular Probes, Eugene, OR) in blocking buffer, stained for 5 min with Hoechst 33342 (0.5 µg/ml) in blocking buffer, washed three
times, and mounted in Vectashield (Vector Laboratories, Burlingame,
CA). Confocal immunofluorescence microscopy was performed with a Leica TCS SP2 system (Leica, Mannheim, Germany).
Statistics. Groups were compared by Student's unpaired t-test and one- or two-way ANOVA as applicable. Statistically significant differences were localized by the Student-Newman-Keuls method. P < 0.05 was considered significantly different in two-tailed tests.
![]() |
RESULTS |
---|
![]() ![]() ![]() ![]() ![]() ![]() ![]() |
---|
Effect of rat size on AICAR-induced 2-DG uptake in EPI muscles.
Most studies of the effect of AICAR on glucose transport in skeletal
muscle have been performed on rat EPI muscles. Due to its rather small
size, this muscle is often obtained from larger rats of ~100-130
g (22, 23) compared with the smaller rats (60-70 g)
from which we usually obtain soleus muscles for studies of glucose
transport regulation (29, 31). Figure
1 shows the effect of 30-min
preincubation with 2 mM AICAR on 2-DG uptake in EPI muscles from four
groups of overnight-fasted rats weighing ~65, 125, 185, and 245 g, respectively. AICAR had the largest effect in muscles from the
smallest rats (P < 0.05), and the effect decreased
progressively in the larger rats. In rats ~65 g, AICAR increased
glucose transport 2.7-fold compared with basal, whereas in muscles from
rats ~245 g transport was increased only 2.1-fold. Muscles were then
obtained from rats weighing between 60 and 70 g in all subsequent
experiments.
|
Time course effect and concentration dependency of AICAR on 2-DG
uptake in EPI, FDB, and soleus muscles.
To find the preincubation time nescessary to give maximum effect of 2 mM AICAR on 2-DG uptake, EPI, FDB, and soleus muscles from 60- to 70-g
overnight-fasted rats were incubated with or without AICAR for either
0, 15, 30, 45, or 60 min at 37°C before transport was assayed at
29°C. Incubation at 37°C without AICAR (basal) resulted in a
progressive increase in glucose transport with time in EPI muscles
(P < 0.05), whereas basal transport in soleus and FDB
muscles was unaffected by incubation for up to 60 min (Fig.
2). Incubation with AICAR gave the
largest increase, both in absolute terms and relative to corresponding
basal values, in EPI muscles. In EPI muscles, the effect peaked after
45 min, whereas in FDB muscles the effect of AICAR was already maximal after 15 min and stayed constant throughout the rest of the 60-min period. In soleus muscles, no effect on 2-DG uptake was observed even
after 60-min incubation with AICAR (Fig. 2). By use of a preincubation
time of 45 min at 37°C with different concentrations (0, 0.5, 1, 2, or 4 mM) of AICAR, it was found that 2 mM gave maximum 2-DG uptake in
EPI muscles, whereas 1 mM gave maximum uptake in FDB muscles (Fig.
3). In the soleus muscle, AICAR had no
effect on 2-DG uptake, even when using 4 mM (Fig. 3). A preincubation time of 45 min at 37°C with or without 2 mM AICAR was then used in
all subsequent experiments.
|
|
Comparison of effects of AICAR and contractions on 2-DG uptake and AMPK activity in different muscles from fed and fasted rats. In EPI and FDB muscles from rats that had been fasted overnight, muscle glycogen concentrations were decreased ~40% (P < 0.05) compared with muscles from fed animals [25.6 ± 2.2 vs. 14.9 ± 1.1 and 23.1 ± 2.6 vs. 14.4 ± 0.8 mmol glycosyl units/kg wet wt (means ± SE), n = 8-10]. In contrast, glycogen concentrations in soleus muscles obtained from fed and fasted animals were not significantly different (21.8 ± 1.0 vs. 19.6 ± 0.9 mmol glycosyl units/kg wet wt, n = 10, P > 0.05).
In muscles from fasted rats, AICAR increased 2-DG transport and total AMPK activity approximately twofold in EPI, less in FDB, and not at all in soleus muscles. In both fed and fasted rats, the effect of contractions on both glucose transport and AMPK activity was always higher than the effect of AICAR (Figs. 4 and 5). Furthermore, the effects of the two stimuli combined on glucose transport was in EPI, but not in the other muscles, partially additive (Fig. 4). In contrast, the effect of combined stimulation on AMPK activity tended in all muscles to be lower than the effect of contractions alone (Fig. 5). Although responses in fed rats in general paralleled those seen in fasted rats, the effect of AICAR, contraction, or both stimuli combined on glucose transport was around twice as high in EPI muscles from fasted compared with fed rats. In fact, AICAR did not significantly increase glucose transport in EPI muscles from fed rats (P > 0.05), despite a similar increase in total AMPK activity, as seen in EPI muscles from fasted rats (Figs. 4 and 5). In FDB and soleus muscles, glucose transport responses were essentially identical in fed compared with fasted rats (Fig. 4). When all mean values from both fed and fasted animals for each muscle were combined, glucose transport varied directly with AMPK activity (Fig. 6). However, the correlation was not significant for EPI muscles (Fig. 6).
|
|
|
AMPK 1- and
2-isoform activity,
expression, and immunohistochemical localization.
To determine which of the two known catalytic isoforms of the
AMPK
-subunit that becomes activated after stimulation,
1- and
2-isoforms were immunoprecipitated
from basal and AICAR- and contraction-stimulated EPI muscles from
fasted rats. AICAR treatment increased the activity of both isoforms
about threefold, and contraction increased the activity of both
isoforms about ninefold compared with basal (Fig.
7). Western blot showed that EPI muscles
had the highest expression of both
1- and
2-isoforms. Furthermore, the soleus had the lowest
expression of
1-AMPK, whereas FDB muscles had the lowest
expression of
2-AMPK (Fig. 8). In an attempt to morphologically
verify the fiber type-specific expression, cryostat sections were
stained with isoform-specific antibodies against either the
1- or
2-subunit. However, the staining
did not reveal any difference between fiber types. In contrast, it was
clearly seen that the
2-, but not the
1-subunit, was highly expressed in nuclei (Fig.
9).
|
|
|
Nucleotide concentrations in muscles from fed and fasted rats.
The inability of AICAR to increase glucose transport and AMPK activity
in soleus muscles might be due to lack of uptake or conversion of AICAR
to ZMP. However, the concentration of ZMP varied between 1 and 2 µmol/g in all three different muscle types, being highest in the FDB
and lowest in the soleus (Table 2). A few
differences were found in nucleotide concentrations between experimental groups. Of note is the finding that AICAR treatment reduced AMP concentrations ~20% in all three muscles, irrespective of the nutritional state (P < 0.05, Table 2).
|
![]() |
DISCUSSION |
---|
![]() ![]() ![]() ![]() ![]() ![]() ![]() |
---|
The focus of the present study was to explore possible fiber type-specific differences in the ability of AICAR and contractions to increase AMPK activity and glucose transport in skeletal muscle. AICAR was first demonstrated to increase glucose uptake, measured as arteriovenous difference, in the perfused rat hindlimb (38), which contains a mixture of predominantly fast-twitch muscle fibers (2). It was proposed that AICAR mimics the effect of contraction on AMPK and, in turn, glucose transport (38). Shortly afterward, it was demonstrated that AICAR treatment of incubated EPI muscles from fasted rats increased glucose transport [measured using 3-O-methylglucose (23)] and GLUT4 translocation (34) and that the effect was additive with the effect of insulin but not additive with the effect of contraction (3, 23). In the present study, we found that AICAR increased glucose transport (measured using 2-DG) in EPI muscles from fasted, but not from fed, rats and, surprisingly, that the combined effect of AICAR and contractions was significantly higher than the effect of each stimulus alone (Fig. 4). This partial additivity suggests that AICAR and contraction activate glucose transport only in part by the same mechanism. The lack of additivity in previous studies (3, 23) compared with the present findings may relate to the different protocols that were used for inducing muscle contractions.
In contrast to our findings in EPI muscles, AICAR-stimulated glucose transport in FDB muscles was rather small (50% vs. 2-fold in EPI) and in soleus muscles was completely absent (Fig. 4). Furthermore, in FDB and soleus muscles, the combined effect of AICAR and contraction on glucose transport was not any different from the effect of contraction alone. This was not due to submaximal effect of AICAR, as a maximum effective dose and exposure time of AICAR had been determined in advance (Figs. 2 and 3). The inconsistencies among different muscles with distinct fiber type compositions (Table 1) were also not due to differential accumulation of ZMP, which reached concentrations between 1 and 2 µmol/g in all three muscles, similar to what has been reported elsewhere (34). This shows that AICAR is taken up and converted to its monophosphorylated form ZMP, irrespective of muscle type. The concentration of ZMP is ~50-fold higher than the endogeneous AMP concentration (Table 2). It may be speculated that ZMP displaces AMP from intracellular binding sites, making it more accessible to degradation. This could provide an explanation for the observation that AICAR treatment reduced AMP concentrations ~20% in all three muscles studied, irrespective of nutritional state (Table 2). However, this is not a universal finding (3, 38), which may be ascribed to methodological differences.
AICAR-stimulated glucose transport was significantly higher (Fig. 4), and glycogen levels lower, in EPI and FDB muscles from fasted than from fed rats (P < 0.05). This corresponds with the fact that both contraction- and insulin-stimulated glucose transport and cell surface GLUT4 content have been shown to correlate negatively with the initial glycogen content (12-14). Accordingly, it is possible that the lack of enhancement by overnight fasting of the AICAR effect in the soleus muscle (Fig. 4) is related to the lack of glycogen depletion during overnight fasting in this muscle. A crucial role of glycogen was suggested more than 15 years ago by studies showing that insulin-independent glucose uptake and transport during and after contraction are increased only if muscle glycogen is below the resting level (16, 41, 45, 46).
It has previously been reported that glucose transport in rat soleus muscle, as also found in the present study, is resistant to acute treatment with AICAR (11), even though this is not a universal finding (3, 17). The discrepancies among various studies observed after acute AICAR treatment of soleus muscles may relate to the nutritional state of the animals or depend on whether experiments were carried out in vitro or in vivo. In one study, 24-h starvation of very small rats (17) may have resulted in glycogen depletion, even in the soleus muscle. In an in vivo study, glucose uptake was also increased in the soleus muscle after intravenous infusion of AICAR (3). However, it cannot be excluded that, in that study, an observed ~50% reduction in plasma free fatty acid levels after AICAR infusion may have contributed to the increase in muscle glucose uptake (19). Recently, it has been reported that treatment of rats for 5 days with subcutaneous injections of AICAR increased insulin-stimulated glucose transport in muscles containing a high proportion of type IIb fibers, but not in soleus muscle, with a majority of type I fibers (5). It thus appears that both acute and chronic treatment with AICAR increase glucose transport mainly in muscles with a high proportion of type IIb fibers. This may indicate that important signaling components in AICAR-stimulated glucose transport are variably expressed in different muscle fiber types.
The mechanism by which AICAR and contraction increase glucose transport
is thought to be through an activation of AMPK (3, 6, 17, 23,
52). If AMPK is an essential intermediary in the signaling
pathway for these two stimuli, then variations in stimulus-induced AMPK
activation are expected to be paralleled by corresponding variations in
glucose transport. In fact, the present study provides such evidence.
In conditions that increased glucose transport, total AMPK activity was
always increased (Figs. 4 and 5). Furthermore, in all muscles and
dietary conditions studied, the effects of contraction on both glucose
transport and total AMPK activity were always higher than the effects
of AICAR (Figs. 4 and 5). Corresponding with this, the effect of
contraction on the activity of the 1- and
2-catalytic subunits of AMPK (see below) was also higher
than the effect of AICAR. When all mean values from both fed and fasted
rats were combined, glucose transport varied directly with total AMPK
activity within each type of muscle (Fig. 6). However, the correlation
was not significant in EPI muscle. The latter finding reflects our
finding that glucose transport in EPI muscles was almost twofold higher
in muscles from fasted compared with fed rats despite identical AMPK
activities. However, it must be kept in mind that the degree of AMPK
activity measured in cell-free extracts only reflects the degree of
phosphorylation of the enzyme, whereas allosteric modifications likely
to play a role in vivo are lost during preparation. Several findings in support of this view have been discussed elsewhere (53).
Another reason for the lack of significant correlation between glucose transport and total AMPK activity in EPI muscle is that, in this muscle, glucose transport was highest upon combined stimulation with
AICAR and contraction, whereas AMPK activity was highest on stimulation
with contraction alone (Fig. 5). In fact, in all three muscles treated
with both AICAR and contraction, the total AMPK activity was decreased
compared with muscles stimulated with contraction alone (Fig. 5). This
decrease in AMPK activity was not due to less force being produced when
muscles were stimulated to contract in the presence of AICAR (data not
shown). However, it is possible that activation of the AMPK is less
efficient when intense contractions producing much AMP are carried out
in the presence of a high intracellular concentration of ZMP (Table 2). It has been shown with purified rat liver AMPK that, at high
concentrations, both AMP and ZMP become less efficient at allosteric
activation of the enzyme, possibly due to competition with ATP at the
catalytic site (9, 26). It is conceivable that a similar
mechanism may be operating for the covalent activation of AMPK by the
upstream kinase and thus may explain the present observation that
combined treatment with contraction and AICAR was less efficient in
activating AMPK than contractions alone (Fig. 5).
Expression of the two isoforms, 1 and
2,
of the catalytic subunit of AMPK did not vary in parallel with fiber
type as determined by Western blot. Furthermore, the two isoforms
showed distinct subcellular compartmentalization, as evidenced by at
least partial nuclear localization of
2 (Fig. 9) but not
1, which has also been observed in INS-1 cells, a
transformed cell line derived from rat pancreatic
-cells
(47). Interestingly, the
2-subunit has been
implicated in the regulation by glucose of islet
-cell gene
expression (10). It may thus be speculated that, in
muscle, the
2-subunit is involved in, for example,
AICAR- and possibly exercise-induced GLUT4 expression (5).
Despite the fact that the combined expression of both isoforms was at
least twice as high in EPI as in FDB or soleus muscles (Fig. 8), basal
and contraction-stimulated total AMPK activity tended to be higher in
the soleus compared with the other two muscles (Fig. 5). The
explanation for this is not readily apparent. However, one possibility
is that, during incubation conditions, the comparatively rather thick
soleus muscle was under more hypoxic stress than the other muscles. In
line with this interpretation, we have found that, in the soleus
muscle, AMPK activity is lower during basal conditions as well as after contraction, when incubation is at 29°C compared with 37°C (data not shown).
Immunoprecipitation with the use of isoform-specific antibodies showed
that both 1- and
2-catalytic subunits of
AMPK are activated by AICAR as well as by muscle contraction (Fig. 7). An effect of AICAR on both isoforms is consistent with previous studies
(22). In contrast, muscle contraction induced by intense electrical stimulation of the sciatic nerve in anesthetized rats increased the activity of only the
2- but not the
1-isoform of AMPK (51). Furthermore, during
high-intensity exercise in humans (~70-75% of maximal oxygen
uptake), only activation of
2, but not
1,
could be detected (18, 53). However, a 30-s bicycle sprint
exercise resulted in a two- to threefold increase in the activity of
both
1- and
2-isoforms in human skeletal muscle (6). It is thus possible that activation of the
1-isoform requires more intense muscle contractions as
used during the present in vitro conditions or during in vivo sprint
exercise (6). It has been suggested that this makes
1 less likely to play a role in the metabolic response
to ordinary exercise in skeletal muscle (18, 51, 53).
Surprisingly, however, also during exercise of relatively low intensity
in humans, where glucose uptake is known to be increased, no activation
of
2 could be detected (18, 53). This
suggests that mechanisms other than activation of AMPK may increase
glucose transport during contractions, which is consistent with several
observations in the present study and with our previous observation
that, in glycogen-supercompensated soleus muscles, glucose
transport was increased sixfold during contractions with no increase at
all in AMPK activity (12). In further support of a
dissociation between AMPK and contraction-stimulated glucose transport,
expression in mouse muscle of a dominant inhibitory mutant of AMPK
completely blocked the ability of hypoxia and AICAR to increase glucose
uptake, whereas the effect of contraction was only partially reduced
(39).
In conclusion, the present study has shown that both AICAR- and
contraction-stimulated glucose transport in muscle vary with muscle
fiber type as well as nutritional state. Contraction is a more potent
stimulus for activation of both glucose transport and AMPK activity
than is AICAR. The amount of AMPK 1- and
2-catalytic subunit isoforms is higher in fast-twitch
than in slow-twitch fibers. Activity of both isoforms is enhanced
by AICAR as well as by contraction, which is consistant with the idea
that AMPK is involved in increasing glucose transport during
contraction. However, several of the present observations may also be
interpreted as indicating a dissociation between AMPK- and
contraction-stimulated glucose transport. For instance, the combination
of contraction plus AICAR reduces total AMPK activity, whereas glucose
transport is either maintained or even increased compared with the
effect of contraction alone. Furthermore, the effect of contraction on AMPK is highest in the soleus muscle, which at the same time has the
smallest contraction-induced glucose transport. Available data are thus
consistent with a scenario in which contraction may enhance glucose
transport by a dual mechanism: a feed-forward control elicited early
during muscle contractions and possibly involving Ca2+ as
well as a feedback control associated with mechanical performance and,
in turn, metabolism and elicited by reduced intracellular energy status
and AMPK (30, 31).
![]() |
ACKNOWLEDGEMENTS |
---|
We thank Gerda Hau and Conni Temdrup for skillful technical help.
![]() |
FOOTNOTES |
---|
This work was supported by grants from the Danish National Research Foundation (504-14), the Velux Foundation, the Danish Diabetes Foundation, and the Novo Nordic Foundation. H. Ai was the recipient of a fellowship sponsered by DANIDA, Danish Ministry of Foreign Affairs. G. Hardie was supported by a Programme Grant from the Wellcome Trust, UK.
Address for reprint requests and other correspondence: T. Ploug, Dept. of Medical Physiology, The Panum Institute, Blegdamsvej 3, DK-2200 Copenhagen N, Denmark (E-mail: t.ploug{at}mfi.ku.dk).
The costs of publication of this article were defrayed in part by the payment of page charges. The article must therefore be hereby marked "advertisement" in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.
10.1152/ajpendo.00167.2001
Received 11 April 2001; accepted in final form 8 January 2002.
![]() |
REFERENCES |
---|
![]() ![]() ![]() ![]() ![]() ![]() ![]() |
---|
1.
Aledo, JC,
Lavoie L,
Volchuk A,
Keller SR,
Klip A,
and
Hundal HS.
Identification and characterization of two distinct intracellular GLUT4 pools in rat skeletal muscle: evidence for an endosomal and an insulin-sensitive GLUT4 compartment.
Biochem J
325:
727-732,
1997[ISI][Medline].
2.
Armstrong, RB,
and
Phelps RO.
Muscle fiber type composition of the rat hindlimb.
Am J Anat
171:
259-272,
1984[ISI][Medline].
3.
Bergeron, R,
Russel RR, III,
Young LH,
Ren J-M,
Marcucci M,
Lee A,
and
Shulman GI.
Effect of AMPK activation on muscle glucose metabolism in conscious rats.
Am J Physiol Endocrinol Metab
276:
E938-E944,
1999
4.
Brooke, MH,
and
Kaiser KK.
Three "myosin ATPase" systems. The nature of their pH lability and sulphydryl dependence.
J Histochem Cytochem
18:
670-672,
1970[ISI][Medline].
5.
Buhl, ES,
Jessen N,
Schmitz O,
Pedersen SB,
Pedersen O,
Holman GD,
and
Lund S.
Chronic treatment with 5-aminoimidazole-4-carboxamide-1-beta-D-ribofuranoside increases insulin-stimulated glucose uptake and GLUT4 translocation in rat skeletal muscles in a fiber type-specific manner.
Diabetes
50:
12-17,
2001
6.
Chen, ZP,
McConell GK,
Michell BJ,
Snow RJ,
Canny BJ,
and
Kemp BE.
AMPK signaling in contracting human skeletal muscle: acetyl-CoA carboxylase and NO synthase phosphorylation.
Am J Physiol Endocrinol Metab
279:
E1202-E1206,
2000
7.
Cheung, PC,
Salt IP,
Davies SP,
Hardie DG,
and
Carling D.
Characterization of AMP-activated protein kinase gamma-subunit isoforms and their role in AMP binding.
Biochem J
346:
659-669,
2000[ISI][Medline].
8.
Coderre, L,
Kandror KV,
Vallega G,
and
Pilch PF.
Identification and characterization of an exercise-sensitive pool of glucose transporters in skeletal muscle.
J Biol Chem
270:
27584-27588,
1995
9.
Corton, JM,
Gillespie JG,
Hawley SA,
and
Hardie DG.
5-Aminoimidazole-4-carboxamide ribonucleoside: a specific method for activating protein kinase in intact cells?
Eur J Biochem
229:
558-565,
1995[Abstract].
10.
Da Silva Xavier, G,
Varadi A,
Ainscow EK,
and
Rutter GA.
Regulation of gene expression by glucose in pancreatic beta-cells (MIN6) via insulin secretion and activation of phosphatidylinositol 3'-kinase.
J Biol Chem
275:
36269-36277,
2000
11.
Dean, DJ,
Kaushik V,
Lin T,
Kurowski T,
and
Ruderman NB.
Stimulation of glucose transport by 5-aminoimidazole-4-carboxamide 1--D-ribofuranoside (AICAR) varies with fiber type.
Diabetes
49, Suppl1:
A193,
2000[ISI].
12.
Derave, W,
Ai H,
Ihlemann J,
Witters LA,
Kristiansen S,
Richter EA,
and
Ploug T.
Dissociation of AMP-activated protein kinase activation and glucose transport in contracting slow-twitch muscle.
Diabetes
49:
1281-1287,
2000[Abstract].
13.
Derave, W,
Hansen BF,
Lund S,
Kristiansen S,
and
Richter EA.
Muscle glycogen content affects insulin-stimulated glucose transport and protein kinase B activity.
Am J Physiol Endocrinol Metab
279:
E947-E955,
2000
14.
Derave, W,
Lund S,
Holman GD,
Wojtaszewski J,
Pedersen O,
and
Richter EA.
Contraction-stimulated muscle glucose transport and GLUT-4 surface content are dependent on glycogen content.
Am J Physiol Endocrinol Metab
277:
E1103-E1110,
1999
15.
Douen, AG,
Ramlal T,
Rastogi S,
Bilan PJ,
Cartee GD,
Vranic M,
Holloszy JO,
and
Klip A.
Exercise induces recruitment of the "insulin-responsive glucose transporter." Evidence for distinct intracellular insulin- and exercise-recruitable transporter pools in skeletal muscle.
J Biol Chem
265:
13427-13430,
1990
16.
Fell, RD,
Terblanche SE,
Ivy JL,
Young JC,
and
Holloszy JO.
Effect of muscle glycogen content on glucose uptake following exercise.
J Appl Physiol Respir Environ Exercise Physiol
52:
434-437,
1982
17.
Fryer, LG,
Hajduch E,
Rencurel F,
Salt IP,
Hundal HS,
Hardie DG,
and
Carling D.
Activation of glucose transport by AMP-activated protein kinase via stimulation of nitric oxide synthase.
Diabetes
49:
1978-1985,
2000[Abstract].
18.
Fujii, N,
Hayashi T,
Hirshman MF,
Smith JT,
Habinowski SA,
Kaijser L,
Mu J,
Ljungqvist O,
Birnbaum MJ,
Witters LA,
Thorell A,
and
Goodyear LJ.
Exercise induces isoform-specific increase in 5'AMP-activated protein kinase activity in human skeletal muscle.
Biochem Biophys Res Commun
273:
1150-1155,
2000[ISI][Medline].
19.
Griffin, ME,
Marcucci MJ,
Cline GW,
Bell K,
Barucci N,
Lee D,
Goodyear LJ,
Kraegen EW,
White MF,
and
Shulman GI.
Free fatty acid-induced insulin resistance is associated with activation of protein kinase C theta and alterations in the insulin signaling cascade.
Diabetes
48:
1270-1274,
1999[Abstract].
20.
Hardie, DG,
and
Carling D.
The AMP-activated protein kinase. Fuel gauge of the mammalian cell?
Eur J Biochem
246:
259-273,
1997[Abstract].
21.
Hardie, DG,
Carling D,
and
Carlson M.
The AMP-activated/SNF1 protein kinase subfamily: metabolic sensors of the eukaryotic cell?
Annu Rev Biochem
67:
821-855,
1998[ISI][Medline].
22.
Hayashi, T,
Hirshman MF,
Fujii N,
Habinowski SA,
Witters LA,
and
Goodyear LJ.
Metabolic stress and altered glucose transport.
Diabetes
49:
527-531,
2000[Abstract].
23.
Hayashi, T,
Hirshman MF,
Kurth EJ,
Winder WW,
and
Goodyear LJ.
Evidence for 5'AMP-activated protein kinase mediation of the effect of muscle contraction on glucose transport.
Diabetes
47:
1369-1373,
1998[Abstract].
24.
Hayashi, T,
Wojtaszewski JF,
and
Goodyear LJ.
Exercise regulation of glucose transport in skeletal muscle.
Am J Physiol Endocrinol Metab
273:
E1039-E1051,
1997[ISI][Medline].
25.
Henin, N,
Vincent MF,
Gruber HE,
and
Van den Berghe G.
Inhibition of fatty acid and cholesterol synthesis by stimulation of AMP-activated protein kinase.
FASEB J
9:
541-546,
1995
26.
Henin, N,
Vincent MF,
and
Van den Berghe G.
Stimulation of rat liver AMP-activated protein kinase by AMP analogues.
Biochim Biophys Acta
1290:
197-203,
1996[ISI][Medline].
27.
Holloszy, JO,
and
Hansen PA.
Regulation of glucose transport into skeletal muscle.
In: Reviews of Physiology, Biochemistry and Pharmacology, edited by Pette D. Heidelberg, Germany: Springer-Verlag, 1996, vol. 128, p. 99-193.
28.
Hutber, CA,
Hardie DG,
and
Winder WW.
Electrical stimulation inactivates muscle acetyl-CoA carboxylase and increases AMP-activated protein kinase.
Am J Physiol Endocrinol Metab
272:
E262-E266,
1997
29.
Ihlemann, J,
Galbo H,
and
Ploug T.
Calphostin C is an inhibitor of contraction, but not insulin-stimulated glucose transport, in skeletal muscle.
Acta Physiol Scand
167:
69-75,
1999[ISI][Medline].
30.
Ihlemann, J,
Ploug T,
Hellsten Y,
and
Galbo H.
Effect of stimulation frequency on contraction-induced glucose transport in rat skeletal muscle.
Am J Physiol Endocrinol Metab
279:
E862-E867,
2000
31.
Ihlemann, J,
Ploug T,
Hellsten Y,
and
Galbo H.
Effect of tension on contraction-induced glucose transport in rat skeletal muscle.
Am J Physiol Endocrinol Metab
277:
E208-E214,
1999
32.
Karlsson, J,
Diamant B,
and
Saltin B.
Muscle metabolites during submaximal and maximal exercise in man.
Scand J Clin Lab Invest
26:
385-394,
1971[ISI].
33.
Kemp, BE,
Mitchelhill KI,
Stapleton D,
Michell BJ,
Chen ZP,
and
Witters LA.
Dealing with energy demand: the AMP-activated protein kinase.
Trends Biochem Sci
24:
22-25,
1999[ISI][Medline].
34.
Kurth-Kraczek, EJ,
Hirshman MF,
Goodyear LJ,
and
Winder WW.
5'AMP-activated protein kinase activation causes GLUT4 translocation in skeletal muscle.
Diabetes
48:
1667-1671,
1999[Abstract].
35.
Lee, AD,
Hansen PA,
and
Holloszy JO.
Wortmannin inhibits insulin-stimulated but not contraction-stimulated glucose transport activity in skeletal muscle.
FEBS Lett
361:
51-54,
1995[ISI][Medline].
36.
Lemieux, K,
Han XX,
Dombrowski L,
Bonen A,
and
Marette A.
The transferrin receptor defines two distinct contraction-responsive GLUT4 vesicle populations in skeletal muscle.
Diabetes
49:
183-189,
2000[Abstract].
37.
Lund, S,
Holman GD,
Schmitz O,
and
Pedersen O.
Contraction stimulates translocation of glucose transporter GLUT4 in skeletal muscle through a mechanism distinct from that of insulin.
Proc Natl Acad Sci USA
92:
5817-5821,
1995
38.
Merrill, GF,
Kurth EJ,
Hardie DG,
and
Winder WW.
AICA riboside increases AMP-activated protein kinase, fatty acid oxidation, and glucose uptake in rat muscle.
Am J Physiol
36:
E1107-E1112,
1997.
39.
Mu, J,
Brozinick JT, Jr,
Valladares O,
Bucan M,
and
Birnbaum MJ.
A role for AMP-activated protein kinase in contraction- and hypoxia- regulated glucose transport in skeletal muscle.
Mol Cell
7:
1085-1094,
2001[ISI][Medline].
40.
Nesher, R,
Karl IE,
and
Kipnis DM.
Dissociation of effects of insulin and contraction on glucose transport in rat epitrochlearis muscle.
Am J Physiol Cell Physiol
249:
C233-C237,
1985[Abstract].
41.
Ploug, T,
Galbo H,
and
Richter EA.
Increased muscle glucose uptake during contractions: no need for insulin.
Am J Physiol Endocrinol Metab
247:
E726-E731,
1984
42.
Ploug, T,
Galbo H,
Vinten J,
Jorgensen M,
and
Richter EA.
Kinetics of glucose transport in rat muscle: effects of insulin and contractions.
Am J Physiol Endocrinol Metab
253:
E12-E20,
1987
43.
Ploug, T,
van Deurs B,
Ai H,
Cushman SW,
and
Ralston E.
Analysis of GLUT4 distribution in whole skeletal muscle fibers: identification of distinct storage compartments that are recruited by insulin and muscle contractions.
J Cell Biol
142:
1429-1446,
1998
44.
Richter, EA.
Glucose utilization.
In: Handbook of Physiology: Regulation and Integration of Multiple Systems. Bethesda, MD: Am. Physiol. Soc, 1996, sect. 12, chapt. 20, p. 912-951.
45.
Richter, EA,
Garetto LP,
Goodman MN,
and
Ruderman NB.
Enhanced muscle glucose metabolism following exercise: evidence for modulation by local factors.
Am J Physiol Endocrinol Metab
246:
E483-E492,
1984
46.
Richter, EA,
Ploug T,
and
Galbo H.
Increased muscle glucose uptake after exercise: no need for insulin during exercise.
Diabetes
34:
1041-1048,
1985[Abstract].
47.
Salt, I,
Celler JW,
Hawley SA,
Prescott A,
Woods A,
Carling D,
and
Hardie DG.
AMP-activated protein kinase: greater AMP dependence, and preferential nuclear localization, of complexes containing the alpha2 isoform.
Biochem J
334:
177-187,
1998[ISI][Medline].
48.
Sevilla, L,
Tomas E,
Munoz P,
Guma A,
Fischer Y,
Thomas J,
Ruiz-Montasell B,
Testar X,
Palacin M,
Blasi J,
and
Zorzano A.
Characterization of two distinct intracellular GLUT4 membrane populations in muscle fiber. Differential protein composition and sensitivity to insulin.
Endocrinology
138:
3006-3015,
1997
49.
Sullivan, JE,
Brocklehurst KJ,
Marley AE,
Carey F,
Carling D,
and
Beri RK.
Inhibition of lipolysis and lipogenesis in isolated rat adipocytes with AICAR, a cell-permeable activator of AMP-activated protein kinase.
FEBS Lett
353:
33-36,
1994[ISI][Medline].
50.
Tullson, PC,
Whitlock DM,
and
Terjung RL.
Adenine nucleotide degradation in slow-twitch red muscle.
Am J Physiol Cell Physiol
258:
C258-C265,
1990
51.
Vavvas, D,
Apazidis A,
Saha AK,
Gamble J,
Patel A,
Kemp BE,
Witters LA,
and
Ruderman NB.
Contraction-induced changes in acetyl-CoA carboxylase and 5'AMP-activated kinase in skeletal muscle.
J Biol Chem
272:
13255-13261,
1997
52.
Winder, WW,
and
Hardie DG.
Inactivation of acetyl-CoA carboxylase and activation of AMP-activated protein kinase in muscle during exercise.
Am J Physiol Endocrinol Metab
270:
E299-E304,
1996
53.
Wojtaszewski, JF,
Nielsen P,
Hansen BF,
Richter EA,
and
Kiens B.
Isoform-specific and exercise intensity-dependent activation of 5'-AMP-activated protein kinase in human skeletal muscle.
J Physiol
528:
221-226,
2000
54.
Woods, A,
Salt I,
Scott J,
Hardie DG,
and
Carling D.
The alpha1 and alpha2 isoforms of the AMP-activated protein kinase have similar activities in rat liver but exhibit differences in substrate specificity in vitro.
FEBS Lett
397:
347-351,
1996[ISI][Medline].
55.
Yeh, J,
Gulve EA,
Rameh L,
and
Birnbaum MJ.
The effects of Wortmannin on rat skeletal muscle.
J Biol Chem
270:
2107-2111,
1995